

## Correction: Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors

In this article (Clin Cancer Res 2013;19:236–46), which was published in the January 1, 2013, issue of *Clinical Cancer Research* (1), on page 243, second column, line 10, the abbreviation BSA is spelled out as "bovine serum albumin" but should read "body surface area." The authors regret this error.

### Reference

1. Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, et al. Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res 2013;19:236–46.

Published OnlineFirst March 15, 2013.

doi: 10.1158/1078-0432.CCR-13-0503

©2013 American Association for Cancer Research.